Table 2. Correlation between BMI1P1 expression and patients parameters.
| Patient's parameters | Status of BMI1P1 expression | ||
|---|---|---|---|
| Low (n = 102) | High (n = 42) | P | |
| Sex, male/female | 63/39 | 18/24 | 0.043 |
| Median age, years (range) | 55.5 (10–93) | 54.5 (15–85) | 0.919 |
| Median hemoglobin, g/L (range) | 75.0 (34–142) | 74 (32–119) | 0.916 |
| Median WBC, ×109/L (range) | 17.7 (0.8–528.0) | 8.2 (0.3–203.6) | 0.131 |
| Median platelets, ×109/L (range) | 36.0 (3–447) | 47.5 (4–190) | 0.351 |
| BM blasts, % (range) | 48.5 (3–97.5) | 28.0 (1–94) | 0.008 |
| FAB | 0.339 | ||
| M0 | 1 (1%) | 0 (0%) | |
| M1 | 6 (6%) | 4 (10%) | |
| M2 | 38 (37%) | 14 (33%) | |
| M3 | 20 (20%) | 12 (29%) | |
| M4 | 22 (22%) | 7 (17%) | |
| M5 | 13 (13%) | 2 (5%) | |
| M6 | 2 (2%) | 2 (5%) | |
| WHO | 0.800 | ||
| AML with t(8;21) | 7 (7%) | 2 (5%) | |
| APL with t(15;17) | 19 (19%) | 11 (26%) | |
| AML with 11q23 translocation | 1 (1%) | 0 (0%) | |
| AML without maturation | 6 (6%) | 3 (7%) | |
| AML with maturation | 30 (29%) | 12 (29%) | |
| Acute myelomonocytic leukemia | 22 (22%) | 7 (17%) | |
| Acute monoblastic and monocytic leukemia | 11 (11%) | 2 (5%) | |
| Acute erythroid leukemia | 2 (2%) | 2 (5%) | |
| No data | 4 (4%) | 3 (7%) | |
| Karyotype classification | 0.707 | ||
| Favorable | 25 (25%) | 13 (31%) | |
| Intermediate | 55 (54%) | 22 (52%) | |
| Poor | 13 (13%) | 4 (10%) | |
| No data | 9 (9%) | 3 (7%) | |
| Karyotype | 0.518 | ||
| normal | 41 (40%) | 20 (48%) | |
| t(8;21) | 7 (7%) | 2 (5%) | |
| t(15;17) | 19 (19%) | 11 (26%) | |
| 11q23 | 1 (1%) | 0 (0%) | |
| complex | 11 (11%) | 4 (10%) | |
| others | 15 (15%) | 2 (5%) | |
| No data | 8 (8%) | 3 (7%) | |
| Gene Mutation* | |||
| C/EBPA (+/−) | 10/82 | 7/28 | 0.242 |
| NPM1 (+/−) | 11/81 | 3/32 | 0.756 |
| FLT3 ITD (+/−) | 15/77 | 1/34 | 0.068 |
| C-KIT (+/−) | 3/89 | 0/35 | 0.561 |
| CR(+/−) | 34/54 | 21/12 | 0.023 |
| BMI1P1 transcript | 0.01 (0–0.14) | 1.48 (0.17–83.09) | < 0.001 |
WBC, white blood cells; FAB, French-American-British classification; AML, acute myeloid leukaemia; CR, complete remission;
*
percentage was equal to the number of mutated patients divided by total cases in each group.